Announcement • Jun 25
NYSE American to Suspend Trading Immediately in Blonder Tongue Laboratories NYSE American LLC (“NYSE American” or the “Exchange”) announced that the staff of NYSE Regulation has now determined to immediately suspend trading in the common stock of Blonder Tongue Laboratories, Inc. (the “Company”) - ticker symbol BDR - from the Exchange. This follows the Exchange’s December 10, 2021 announcement initiating delisting proceedings. The Company had requested a review of the NYSE American delisting determination before a Committee of the Board of Directors of the Exchange. On June 24, 2022, the Company provided formal notification of its intention to withdraw its request for such review. Accordingly, the NYSE American will now suspend trading in the common stock and will file a delisting application with the Securities and Exchange Commission. Announcement • Dec 13
NYSE American to Commence Delisting Proceedings Against Blonder Tongue Laboratories NYSE American LLC announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Blonder Tongue Laboratories, Inc. from the Exchange. NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1009(a) of the NYSE American Company Guide (the “Company Guide”) as the Company was unable to demonstrate that it had regained compliance with all of Sections 1003(a)(i), (ii) and (iii) of the Company Guide by the end of the maximum 18-month compliance plan period, which expired on December 10, 2021. The Company has a right to a review of staff’s determination to delist the common stock by a committee of the Board of Directors of the Exchange (the “Committee”). Following such appeal, a decision by the Committee will be made and announced by NYSE Regulation regarding either proceeding with suspension and delisting or continued trading in the Company’s common stock. If the Company does not appeal this determination, NYSE American will announce the date that trading will be suspended. The filing of an application with the Securities and Exchange Commission to delist the common stock is pending completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision. Announcement • Dec 13
Blonder Tongue Laboratories Receives Non-Compliance Letter from NYSE American Blonder Tongue Laboratories, Inc. announced that it has received notice from NYSE American LLC (“NYSE American”) that it is not in compliance with the continued listing standard set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”). That section applies if a listed company has stockholders’ equity of less than $4 million and has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Company reported stockholders’ equity of $2,614,000 as of September 30, 2020, the end of its most recent fiscal quarter, and has had losses from continuing operations and/or net losses in each of its five most recent fiscal years including the fiscal year ended December 31, 2019. This notice is in addition to the notice the Company received from NYSE American on June 10, 2020, notifying the Company that it was not in compliance with the continued listing standard set forth in Section 1003(a)(iii) of the Company Guide because the Company reported stockholders’ equity of less than $6 million as of March 31, 2020 and reported losses from continuing operations and/or net losses in each of its five most recent fiscal years ended December 31, 2019. The Company submitted a detailed financial plan to regain compliance with the listing standard set forth in Section 1003(a)(iii) to NYSE American and on August 27, 2020, the Company received notice that its plan had been accepted and that the Company had been granted a plan period through December 10, 2021. The December 10, 2021 deadline will also apply to the notice regarding noncompliance with Section 1003(a)(ii) of the Company Guide. As a result, the Company must be in compliance with Section 1003(a)(ii) and Section 1003(a)(iii) by that deadline. Further, the proposed plan submitted by the Company and approved by the NYSE American on August 27, 2020 included an expectation and anticipation of stockholder’s equity falling below the $4 million threshold before improving to compliance before the December 10, 2021 deadline. The listing of the Company’s common stock on NYSE American is being continued during the plan period pursuant to an extension. During the plan period the Company will be subject to periodic review by NYSE Regulation staff, including quarterly monitoring, to determine if the Company is making progress consistent with the plan. If the Company is not in compliance with the continued listing standards by December 10, 2021, or if NYSE Regulation determines that the Company is not making sufficient progress consistent with the plan, delisting proceedings will may be instituted against the Company, as appropriate. Announcement • Sep 04
NYSE Accepts Compliance Plan of Blonder Tongue Laboratories, Inc Blonder Tongue Laboratories, Inc. announced that it has received notice from NYSE Regulation that it has accepted the Company's plan to regain compliance with the NYSE American LLC ("NYSE American") continuing listing standard provided in Section 1003(a)(iii) of the NYSE American Company Guide ("Section 1003(a)(iii)"). As previously disclosed, on June 10, 2020, the Company received notification (the "Non-Compliance Notice") from NYSE American that the Company was not in compliance with Section 1003(a)(iii). That section applies if the reported stockholders' equity of the listed company is less than $6 million and the listed company has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The Non-Compliance Notice indicated that the Company reported stockholders' equity of $5.4 million as of March 31, 2020 and reported losses from continuing operations and/or net losses in each of its five most recent fiscal years ended December 31, 2019, resulting in the Company failing to comply with the continued listing standard. As a result, the Company was required to submit a plan to NYSE American by July 10, 2020 addressing how the Company intends to regain compliance with Section 1003(a)(iii) by December 10, 2021. In accordance with NYSE American's policies and procedures, the Company submitted its plan of compliance prior to the deadline. On August 27, 2020, the Company received notice from NYSE Regulation that it had accepted the Company's plan to regain compliance with Section 1003(a)(iii) and granted a plan period through December 10, 2021. The listing of the Company's common stock on NYSE American is being continued during the plan period pursuant to an extension. In addition, during the plan period the Company will be subject to periodic review by NYSE Regulation staff, including quarterly monitoring, to determine if it is making progress consistent with the plan. If the Company is not in compliance with the continued listing standards by December 10, 2021, or if the Company does not make sufficient progress consistent with its plan, NYSE Regulation staff will initiate delisting proceedings as appropriate. If that were to occur, the Company would have the right to appeal any delisting determination. The Company can provide no assurances that it will be able to make progress with respect to its plan that NYSE Regulation will determine to be satisfactory, that it will regain compliance with Section 1003(a)(iii) on or before the expiration of the plan period, or that developments and events occurring subsequent to the Company's formulation of the compliance plan or its acceptance by NYSE Regulation will not adversely affect the Company's ability to make sufficient progress and/or regain compliance with Section 1003(a)(iii) on or before the expiration of the plan period or result in the Company's failure to be in compliance with other NYSE American continued listing standards. Receipt of the notice from NYSE Regulation accepting the Company's plan does not affect the Company's business, operations or reporting requirements with the Securities and Exchange Commission, and the Company's common stock will continue to be listed and traded on NYSE American, subject to periodic review by NYSE Regulation. Announcement • Jun 18
Blonder Tongue Announces Receipt of Noncompliance Notice from NYSE American Blonder Tongue Laboratories, Inc. (NYSE American: BDR) announced that it has received notice from NYSE American LLC ("NYSE American") that it is not in compliance with the continued listing standard set forth in Section 1003(a)(iii) of the NYSE American Company Guide (the "Company Guide"). That section applies if a listed company has stockholders' equity of less than $6 million and has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The Company reported stockholders' equity of $5.4 million as of March 31, 2020, the end of its first fiscal quarter of 2020, and has had losses from continuing operations and/or net losses in each of its five most recent fiscal years including the fiscal year ended December 31, 2019. As a result, the Company has become subject to the procedures and requirements of Section 1009 of the Company Guide and must submit a plan to NYSE American by July 10, 2020 addressing how the Company intends to regain compliance with Section 1003(a)(iii) by December 10, 2021.